Company intelligence / Profile preview

TruBiotics

Phoenix, Arizona, United States

Ownership: Private
Development stage: Other

Overview

TruBiotics is a leading consumer health brand specializing in probiotic supplements designed to support digestive and immune health. Originally developed and launched by Bayer, the brand was acquired by PanTheryx in 2021 to anchor its consumer biologics portfolio. The product line features proprietary blends of probiotic strains, such as Bifidobacterium animalis BB-12 and Lactobacillus acidophilus LA-5, which are clinically studied for their efficacy in maintaining gut flora balance. TruBiotics operates as a commercial-stage entity within the broader nutraceutical and functional food market.

Therapeutic areas: ImmunologyGastroenterology
Modalities: Microbial therapyLive biotherapeutic product therapy
Industry: Food & Nutrition

Beyond the preview

Go deeper on TruBiotics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TruBiotics.

Explore the full profile